Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

    ... Zarnestra, Revlimid, arsenic, SAHA inhibitors, or any investigational medication; a minimum of five days must have elapsed since the ... to starting study drug; Congestive heart failure (CHF) New York (NY) Heart Association class III or IV; Patients with an ejection ...

    Clinical Trial last updated 06/03/2016 - 2:24pm.

  2. Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    ... participant without clinically significant encephalopathy/new focal deficits Infectious diseases: no clinical evidence of ... 4 weeks of enrollment Currently enrolled in another investigational therapy protocol Participants with presence of ...

    Clinical Trial last updated 07/14/2016 - 4:08pm.

  3. Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

    ... of the study drug. Patients should not have received an investigational agent for at least 2 weeks prior to the first study drug dose. ... atrophy). Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment. NB: ...

    Clinical Trial last updated 06/06/2016 - 10:59am.

  4. Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

    ... (> 5cm from initiation of hydroxyurea) or the appearance of new splenomegaly or hepatomegaly while on MTD of hydroxyurea. Not achieving ... Thyroid dysfunction not adequately controlled Any investigational drug <6 weeks prior to the first dose of study drug or not ...

    Clinical Trial last updated 04/29/2016 - 9:59am.

  5. PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation (FLUBUTBI)

    ... infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section ... as not medically relevant Patient has received other investigational drugs with 14 days before enrollment Serious medical or ...

    Clinical Trial last updated 04/29/2016 - 3:09pm.

  6. Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)

    ... multiple tumor-associated antigen (TAA)-specific T cells (a new experimental therapy) to treat patients with acute myeloid leukemia (AML) ... These donor-derived multiTAA-specific T cells are an investigational product not yet approved by the U.S. Food and Drug ...

    Clinical Trial last updated 04/28/2016 - 11:40am.

  7. Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (BMT)

    ... called graft versus host disease (GVHD) where the new donor cells attack the recipient's normal body. Recently, less intense ... Active serious infection Participation in other investigational drug use at the time of enrollment Contraindication to ...

    Clinical Trial last updated 05/09/2016 - 3:36pm.

  8. Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation

    ... dose of azacitidine. Men must be willing not to father a new child while receiving therapy. They must use an effective barrier method of ... days after transplant. Must not be receiving any other investigational agents within 14 days of first dose of azacitidine (Day ...

    Clinical Trial last updated 05/02/2016 - 2:07pm.

  9. FAQs

    ... number of people who have MDS is not known, about 10,300 new cases were reported in the U.S. in 2003. This number was taken from data ... and are up-to-date on both the standard therapies and new investigational treatments. Though AA&MDSIF does not refer specialists, ...

    Topic section last updated 03/02/2016 - 11:42am.